JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$4.76B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.21B |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$3.81B |
| 4 |
Apple
AAPL
|
+$3.39B |
| 5 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$3.1B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total International Bond ETF
BNDX
|
+$2.48B |
| 2 |
S&P Global
SPGI
|
+$2.45B |
| 3 |
Coca-Cola
KO
|
+$1.73B |
| 4 |
Adobe
ADBE
|
+$1.59B |
| 5 |
Schwab Short-Term US Treasury ETF
SCHO
|
+$1.3B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.97% |
| 2 | Technology | 21.69% |
| 3 | Healthcare | 9.58% |
| 4 | Consumer Discretionary | 9.07% |
| 5 | Financials | 8.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
FTH
6426
Faeth Therapeutics
FTH
$717M
| $701 | ﹤0.01% |
33
| – | – |
2021 Q1
12 quarters
|
|
6427
iShares MSCI Japan Value ETF
EWJV
$783M
| $698 | ﹤0.01% |
+21
| New | +$655 |
2024 Q1
0 quarters
|
|
|
PHX
6428
DELISTED
PHX Minerals
PHX
| $692 | ﹤0.01% |
203
-9,731
| -98% | -$30.4K |
2017 Q3
26 quarters
|
|
|
SOL
6429
DELISTED
Emeren Group
SOL
| $691 | ﹤0.01% |
+358
| New | +$730 |
2024 Q1
0 quarters
|
|
|
BORR
6430
PUT
Borr Drilling
BORR
$1.27B
| $685 | ﹤0.01% |
100
| – | – |
2023 Q1
4 quarters
|
|
|
PARAW
6431
Banzai International Warrant
PARAW
$118K
| – | – |
0
| – | – |
2022 Q1
8 quarters
|
|
6432
TherapeuticsMD
TXMD
$23.7M
| $671 | ﹤0.01% |
293
| – | – |
2015 Q1
36 quarters
|
|
6433
ALPS Clean Energy ETF
ACES
$99M
| $663 | ﹤0.01% |
22
-41
| -65% | -$1.24K |
2022 Q4
5 quarters
|
|
6434
Aligos Therapeutics
ALGS
$33.5M
| $663 | ﹤0.01% |
27
| – | – |
2020 Q4
13 quarters
|
|
|
GTH
6435
DELISTED
Genetron Holdings Limited ADS
GTH
| $652 | ﹤0.01% |
+162
| New | +$622 |
2024 Q1
0 quarters
|
|
6436
Innovator US Equity Buffer ETF July
BJUL
$360M
| $645 | ﹤0.01% |
16
| – | – |
2023 Q3
2 quarters
|
|
|
BEST
6437
DELISTED
BEST Inc. American Depositary Shares, each representing twenty (20) Class A Ordinary Shares
BEST
| $627 | ﹤0.01% |
+285
| New | +$650 |
2024 Q1
0 quarters
|
|
6438
Oxford Square Capital
OXSQ
$137M
| $615 | ﹤0.01% |
194
-91
| -32% | -$278 |
2022 Q4
5 quarters
|
|
6439
CytomX Therapeutics
CTMX
$553M
| $613 | ﹤0.01% |
281
| – | – |
2016 Q4
29 quarters
|
|
|
QNRX
6440
Quoin Pharmaceuticals
QNRX
$9.3M
| $612 | ﹤0.01% |
+18
| New | +$1.78K |
2024 Q1
0 quarters
|
|
6441
BlackRock ESG Capital Allocation Term Trust
ECAT
$1.39B
| $608 | ﹤0.01% |
35
-14,195
| -100% | -$237K |
2022 Q4
5 quarters
|
|
|
CYPH
6442
Cypherpunk Technologies Inc
CYPH
$318M
| $604 | ﹤0.01% |
227
-40
| -15% | -$120 |
2021 Q4
9 quarters
|
|
6443
Genasys
GNSS
$66M
| $602 | ﹤0.01% |
254
-562
| -69% | -$1.04K |
2022 Q3
6 quarters
|
|
|
CMPS
6444
Compass Pathways
CMPS
$1.6B
| $599 | ﹤0.01% |
72
| – | – |
2021 Q2
11 quarters
|
|
6445
FingerMotion
FNGR
$21M
| $599 | ﹤0.01% |
+285
| New | +$729 |
2024 Q1
0 quarters
|
|
6446
Nuveen Real Asset Income & Growth Fund
JRI
$388M
| $593 | ﹤0.01% |
50
| – | – |
2023 Q1
4 quarters
|
|
6447
Nektar Therapeutics
NKTR
$1.43B
| $589 | ﹤0.01% |
42
| – | – |
2013 Q2
43 quarters
|
|
6448
Sprott Copper Miners ETF
COPP
$286M
| $583 | ﹤0.01% |
+25
| New | +$552 |
2024 Q1
0 quarters
|
|
6449
VanEck Steel ETF
SLX
$162M
| $581 | ﹤0.01% |
8
| – | – |
2020 Q4
13 quarters
|
|
|
PPBT
6450
Purple Biotech
PPBT
$2.44M
| $575 | ﹤0.01% |
+4
| New | +$574 |
2024 Q1
0 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2024 Portfolio in Review
As of Q1 2024, JP Morgan Chase held 8,132 positions worth $1.18T, up 14% from $1.04T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
JP Morgan Chase deployed $48.7B of net new capital in Q1 2024, opening 625 new positions and adding to 3,255 existing holdings. Its largest new stake was Flutter Entertainment: 1,314,201 shares worth $260M.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Vanguard Total International Bond ETF, an estimated $2.48B trimmed.
- JP Morgan Chase's largest Q1 2024 buy was Flutter Entertainment: 1,314,201 shares worth $260M.
- JP Morgan Chase added most to Vanguard S&P 500 ETF in Q1 2024, an estimated $4.76B increase.
- JP Morgan Chase's biggest Q1 2024 reduction was Vanguard Total International Bond ETF, cutting an estimated $2.48B.
- JP Morgan Chase fully exited BlackRock Flexible Income ETF in Q1 2024, selling an estimated $139M.
- JP Morgan Chase's ten largest holdings make up 21% of its $1.18T portfolio in Q1 2024.
- JP Morgan Chase opened 625 new positions and closed 764 in Q1 2024.
- JP Morgan Chase's portfolio value rose 14% quarter-over-quarter to $1.18T.
Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.